Intarcia Appoints Thane Wettig as Chief Marketing Officer and Metabolic Franchise Head
Published: Jul 03, 2018
Wettig Brings Strong Background in Diabetes and Metabolic Diseases from Leading Global Diabetes Company
BOSTON, July 3, 2018 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Thane Wettig to the newly created role of Chief Marketing Officer (CMO) and Metabolic Franchise Head. Wettig will report directly to Kurt Graves, Chairman, President and CEO of Intarcia, and will serve on the company's executive leadership team. In his role as CMO, Wettig will lead Intarcia's marketing team, while simultaneously spearheading the implementation of the fully integrated launch plan for ITCA 650, the company's lead investigational therapy for the treatment of type 2 diabetes (T2D) and the development of Intarcia's metabolic assets in the pipeline.
"Thane is a well-rounded, accomplished leader with deep expertise in the diabetes and metabolic space. He strengthens our organization with deep therapeutic and commercial leadership and brings to us a wealth of best practices, with a proven track record of building high-performing teams that can bring innovative therapies from development to market," said Kurt Graves. "I know I speak on behalf of everyone at Intarcia when I say we are excited and confident Thane will have a tremendous impact on the future of our company."
Wettig brings extensive diabetes marketing experience to Intarcia. In his most recent role, he served as the Chief Marketing Officer for Lilly Diabetes, Eli Lilly & Co.'s largest therapeutic area, where he led a team of more than 60 professionals responsible for new product development, brand management, market research and market access. Wettig has extensive experience in the creation, launch and evolution of multiple blockbuster diabetes brands and delivery devices including Humalog, Byetta, Bydureon, Trajenta, Jardiance, Trulicity and Basaglar. Wettig also served as the commercial lead for the negotiation, structure and ongoing management of the Lilly/Boehringer-Ingelheim diabetes alliance. He began his career at Lilly as a primary care sales rep, where he established himself as a top performer, and gained additional leadership and general management experiences in business development, sales leadership and Lilly's German operation.
"Throughout my career, I've been driven by a mission to improve the outcomes of people with diabetes," commented Wettig on his appointment. "This is a transformative moment in time for the future of type 2 diabetes management, and I believe that Intarcia's lead product and pipeline have the potential to help shape the future of treatment for diabetes. I'm excited to lead a team that is working relentlessly to reinvent the way medicine is delivered to patients in need."
For more information about Thane and other members of Intarcia's leadership team members, please visit our website.
About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment and prevention outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Delivering medicines just once- or twice yearly to prevent and/or chronically treat diseases holds potential to improve outcomes by improving effectiveness over time and by addressing real-world unmet needs around poor patient adherence and persistence rates that are high in the majority of chronic diseases. Intarcia is investigating multiple therapies, including combination therapies, for chronic diseases leveraging the convergence of novel medicines and the proprietary Medici Drug Delivery System™. Intarcia is developing a strong pipeline in important therapeutic areas, including: diabetes (ITCA 650), obesity, autoimmune diseases, HIV, and other serious disorders.
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc.
SOURCE Intarcia Therapeutics, Inc.